Workflow
生物3D打印
icon
Search documents
北京敏速智造:以生物3D打印技术赋能医疗创新,亮相行业论坛开启新征程
DT新材料· 2025-07-12 13:58
Core Viewpoint - Beijing MinSu Intelligent Manufacturing Biotechnology Co., Ltd. is emerging as a key player in the biomanufacturing sector, showcasing its innovative 3D bioprinting technologies and services at the upcoming 2025 Polymer 3D Printing Materials Summit [1][17]. Group 1: 72-Hour Printing Test Feedback - The company offers a "72-hour printing test feedback platform" aimed at accelerating research and clinical translation by providing efficient feedback on printing results [2][3]. - For users without equipment, the company provides "printing services" that include material selection, scaffold design, and printing, delivering results within 72 hours along with detailed test reports [2]. - For users with equipment, the company offers remote technical guidance and on-site support to optimize printing parameters and scaffold designs, enhancing experimental success rates [2]. Group 2: Diverse Equipment Layout - The company has developed a multi-tiered equipment system centered around the PanoSpace brand, covering a complete product line from education to research and single-material to multi-material applications [4]. - Key products include the MEWOne system for micro-scale precision structures, the BioPro platform for various printing applications, and the BiOne system for dual-material printing [4][6][8]. - The modular design of the equipment reduces maintenance costs and enhances adaptability, making it a standard choice for institutions like Tsinghua Chang Gung Hospital and Beijing University of Chinese Medicine [9]. Group 3: Precision Supporting Materials and Scaffold Solutions - The company provides a comprehensive service package that includes printing materials, scaffold structures, and experimental parameters to improve model fidelity [10]. - The material library covers mainstream bioprinting materials such as PCL, PLA, PLGA, GelMA, and HAMA, along with detailed experimental parameter guidelines [10]. - This approach has reportedly improved organoid culture efficiency by 30% and reduced validation cycles by 50% [11]. Group 4: Redefining Industry Service Models - The company is shifting from a traditional equipment sales model to a results delivery model, integrating printing, testing, and feedback into a cohesive service system [14]. - This new model significantly lowers entry barriers and enhances project validation efficiency, particularly for academic labs, startups, and research institutions [14]. Group 5: Strategic Focus for 2025 - Looking ahead to 2025, the company plans to deepen its dual strategy of "testing services and platformization" [15]. - Key focus areas include the development of a digital Biolab system for integrated printing and testing, clinical applications in skin repair and cartilage replacement, and collaborative efforts in bioprinting scaffold testing [15].
EFL创始人,浙大贺永教授:生物3D打印机赋能器官模型构建与器官体外再造
DT新材料· 2025-07-09 14:48
Core Viewpoint - EFL is focused on the development and application of bioprinting technologies, particularly in regenerative medicine, showcasing its innovations at the upcoming 2025 Polymer 3D Printing Materials Summit [1][21]. Company Overview - EFL was established in 2017, leveraging research outcomes from Zhejiang University led by Professor He Yong [2]. - The company provides comprehensive services in regenerative medicine, encompassing scientific popularization, research services, and technology transfer [3]. Product Offerings - EFL offers several advanced products: - **Volume Photopolymerization Bioprinter**: Capable of rapid formation of cell-laden hydrogel structures with a 4K projection accuracy [4]. - **Multi-functional Extrusion Bioprinter**: Features a wide temperature control range of -25 to 260°C, suitable for various bioprinting materials [8]. - **Projection Photopolymerization Bioprinter**: Supports automatic switching of up to six inks for complex bioprinting needs [12]. - **Microneedle Manufacturing Device**: The first multifunctional desktop device for preparing hydrogel microneedles, integrating humidity and vacuum control systems [17]. - **Gelatin Methacryloyl (GelMA)**: A versatile hydrogel with excellent biocompatibility and mechanical properties, suitable for 3D cell culture and tissue engineering [19]. Technical Highlights - The bioprinters boast high printing speeds, with structures forming in seconds, and maintain a cell viability rate exceeding 95% [5][9][13]. - The devices are designed for various applications, including cell culture scaffolds, organoids, and organ-on-a-chip technologies [5][9][13]. Market Position - EFL ranks among the top three in the domestic bioprinting research market, with its photopolymerization bioprinting inks holding the leading market share [6][10][14].
捷诺飞生物科技:高性能生物3D打印机助力再生医学新发展
DT新材料· 2025-07-03 13:38
Core Viewpoint - Hangzhou Regenovo Biotechnology Co., Ltd. is a leading provider of biological 3D printing technology and solutions in regenerative medicine, showcasing its advanced products and research at the upcoming 2025 Polymer 3D Printing Materials Summit Forum [2][35]. Group 1: Company Overview - Founded in 2013, Hangzhou Regenovo Biotechnology specializes in biological 3D printing technology, biomaterials, and regenerative medicine [2][43]. - The company offers a comprehensive range of services, including digital design, cell amplification, biological 3D printing, and quantitative detection [2][47]. - Regenovo has developed domestic alternatives for biodegradable biomedical materials and provides live tissue models for pharmaceutical and cosmetic evaluations [2][47]. Group 2: Business Model - The business model includes providing additive manufacturing equipment and materials, along with customized solutions for clients [3][47]. - The company also offers additive manufacturing services to produce complex components or products for various applications [3][47]. Group 3: Product Offerings - Regenovo's product line includes: - Bio-Architect® SR PRO: A high-performance desktop biological 3D printer designed for small to medium-sized research labs [4][11]. - Bio-Architect® WS: A workstation-level biological 3D printer suitable for interdisciplinary research [12][18]. - Bio-Architect® SR: A desktop biological 3D printer for exploratory research in regenerative medicine [18][24]. - Bio-Architect® PR PRO: A high-precision DLP biological 3D printer for tissue engineering and organ-on-chip applications [25][29]. - Bio-Architect® PR: A multi-material DLP printer for micro-needle and microfluidic chip applications [30][34]. Group 4: Technological Innovations - Regenovo has undertaken significant national research projects and holds 179 patents related to biological 3D printing and materials [35]. - The company integrates AI algorithms to enhance printing efficiency and model fidelity in organ-like structures [35]. - Innovations include deep learning for system calibration and monitoring, as well as machine learning for non-destructive testing of 3D printed organ models [35]. Group 5: Upcoming Events - The founder, Xu Ming'en, will present on "Intelligent Manufacturing and Detection Technology Equipment Research for Biomaterials" at the 2025 Polymer 3D Printing Materials Summit Forum [1][35].
华夏司印:3D打印如何抓住万亿骨软骨再生医学市场
DT新材料· 2025-07-02 15:18
Core Viewpoint - The rapid development of medical 3D printing technology, particularly in the field of organ printing, is highlighted, with significant market growth expected in China's medical device sector and the knee cartilage repair market by 2030 [2][16]. Group 1: Medical 3D Printing Market - The Chinese medical device market is projected to exceed 1.2 trillion yuan by 2025, with a compound annual growth rate (CAGR) of 7.53% over the next six years [2]. - The overall market for knee cartilage repair in China is expected to reach between 16 billion to 30 billion yuan by 2030 [2]. Group 2: Bioink and Its Applications - Photosensitive natural bio-3D printing materials (bioink) exhibit excellent biocompatibility, absorbability, and printability, supporting cell growth and tissue regeneration [2]. - Bioink applications in regenerative medicine include organoids, tissue engineering scaffolds, and drug delivery systems, driving advancements in personalized medicine [2]. Group 3: Company Profile and Innovations - 华夏司印 (Shanghai) Biotechnology Co., Ltd. is at the forefront of the medical 3D printing industry, offering 12 bioink formulations capable of printing 90% of human tissues and organs [3][4]. - The company has developed a "bio-3D printing gun" for clinical validation in collaboration with Shanghai Ruijin Hospital, aimed at minimally invasive cartilage repair [4]. Group 4: Challenges and Future Directions - The bone and cartilage regeneration market is characterized by unmet clinical needs and a lack of products in China, but advancements in biomaterials and stem cell technology are paving the way for growth [16]. - The bio-3D printing process involves six steps, emphasizing the need for component, structural, and mechanical biomimicry to achieve effective regeneration [17]. - The establishment of industry standards for bioink and its standardized mass production is crucial for the advancement of regenerative medicine [17].